Trial Profile
A Phase 2, Open-Label, Single-Center, Extension Study Evaluating Antibody Persistence Compared to Naive Children and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received a Three-Dose Series of the Novartis Vaccine as Infants in Study V72P9
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jul 2019
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine group B OMV Novartis (Primary) ; Meningococcal vaccine group B
- Indications Meningococcal group B infections
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Novartis Vaccines
- 28 Apr 2014 New source identified and integrated (United Kingdom Clinical Research Network, 7297)
- 28 Apr 2014 New trial record